Skip to content
InSilens, Biotech Intelligence
Login
  • Home
  • Signals
  • Contact us
  • Subscribe
Explore the platform
InSilens, Biotech Intelligence
INSILENS, A Noetera Company

Biotech Intelligence Platform

Turn Global Biotech Signals, Into Strategic Intelligence

Explore with us

Biotech Signals. Structured for Decisions.

INSILENS converts global biotech activity into decision-grade intelligence for investors, executives, and business development teams.

Deals and Financing
Lilly + Ascidian – $1.9B RNA Exon Editing Deal
June 3, 2026
YolTech – In Vivo CRISPR/Base Editing Platform Financing
May 28, 2026
Waypoint Bio – China IIT CAR-T Strategy
May 27, 2026
BMS – Anthropic AI Partnership
May 20, 2026
Therapeutic Indication
Karyopharm – SENTRY Phase 3 Full Data in Frontline Myelofibrosis
June 2, 2026
Kelonia Therapeutics – In Vivo CAR-T Clinical Update
June 1, 2026
TUNE-401 Epigenetic Silencing Clinical PoC
June 1, 2026
Karyopharm – SENTRY Phase 3 Myelofibrosis Readout Watch
June 1, 2026
Technology Modalities
Regeneron – Gene Therapy Approved for Hearing Loss
April 24, 2026
Cartherics – CAR-NK Manufacturing Expansion
April 15, 2026
Life Biosciences – $80M Gene Therapy Financing
April 9, 2026
Orca Bio – FDA Extends Orca-T Review Timeline
April 9, 2026
View all

Weekly Market Insight

Regeneron – MFN Drug Pricing Agreement
Lilly – Ajax JAK2 Deal ($2.3B)
Takeda – Rusfertide US Rights Deal
Fortress Biotech, $205M Priority Review Voucher Sale
    • Home page
    • Signals
    • Contact us
    • Subscribe

 

  • Deals and Financing
  • Therapeutic Indication
  • Technology Modalities

Contact Us

Need help or have a question?
Contact us at: info@insilens.com

  • Privacy Policy
  • Terms & Conditions

 

Our company

InSilens is a biotech intelligence platform transforming global signals into actionable insights for investors, researchers, and industry leaders. A product of Noetera.

© 2026 InSilens. All rights reserved. A Noetera Company